Dr. Simon William Beaven, MD

Dr. Beaven practices at Olive View-UCLA Medical Center in Sylmar, California, part of County of Los Angeles.

Dr. Beaven's NPI, 1205018967, was assigned on December 4, 2007. Dr. Beaven graduated from UCSF School of Medicine in 2001. Dr. Beaven holds California license A83692.

Dr. Beaven's primary practice is Olive View-UCLA Medical Center, at 14445 Olive View Drive, Sylmar, CA 91342 in Los Angeles County. The practice phone is (818) 364-1555.

Dr. Beaven's primary practice is Olive View-UCLA Medical Center in Sylmar, California, part of County of Los Angeles. Dr. Beaven is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is Harbor-UCLA Medical Center. Dmand AI also links Dr. Beaven to 1 more hospital, 2 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Beaven practices, 5 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Beaven's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Beaven is board certified in gastroenterology by the American Board of Internal Medicine. Dr. Beaven is licensed in California.

Dmand AI lists cirrhosis of the liver and fatty liver among the conditions Dr. Beaven treats.

CMS data shows 45 Medicare services from Dr. Beaven across 1 procedure code in 2024, all of them office visits, for 59 Medicare patients. Medicare paid $3,052 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 59 Medicare patients who saw Dr. Beaven in 2024. The largest group is 65 to 74, with 38 patients. 71% of them have high cholesterol, and 66% have high blood pressure. 39% are also on Medicaid. Their average risk score is 1.92, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Beaven's median patient age at 63, with 54% women.

In 2024, Dr. Beaven wrote 260 Medicare Part D claims for 74 patients. 80% of them were for generic drugs. CMS names the drug for 165 of them, across 8 drugs with 11 or more claims each, at $59,739 in total drug cost. In 2023, CMS named 114 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Beaven for performance year 2024, reported as part of a group. Dr. Beaven accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Beaven as offering telehealth.

Dmand AI links 3 papers to Dr. Beaven. Dr. Beaven's most frequent co-authors are Karl E. Anderson, MD, Vivek Ashok Rudrapatna, MD, PhD and Vivek Rudrapatna, MD.

Dmand AI links Dr. Beaven to 1 clinical trial. Conditions studied include Liver Cirrhosis and Non-alcoholic Fatty Liver Disease.

CMS Open Payments shows 37 general payments to Dr. Beaven from 11 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 92% of the total. Alnylam Pharmaceuticals Inc. paid the most, $22,984.

Dr. Beaven graduated from UCSF School of Medicine in 2001. Dr. Beaven is a member of American Association for the Study of Liver Diseases (AASLD) and AGA.

Dr. Beaven is in network with 6 carriers, including Blue Cross Blue Shield of Michigan, Blue Cross Blue Shield of Massachusetts and HCSC. Medicare plans come from the most carriers, 5. Check the plan with the practice before a visit.